Gene therapy in cardiovascular disorder market is estimated to be worth US$ 178 million in 2023 and is projected to reach US$ 1,351.3 million by 2030, growing at a CAGR of 21.1% during the forecast period 2024-2030.

This significant growth is driven by factors such as rising prevalence of cardiovascular diseases, increasing investments in gene therapy research and development, and growing government support for research.

Gene therapy offers a promising treatment option for patients with cardiovascular disorders, with the potential to address the underlying genetic causes of disease and provide long-term benefits.

To Know more about this report (Description, TOC and List of Tables and Figures) — Gene therapy in cardiovascular disorder market

Key Players:

• Renovacor
• Gene Biotherapeutics
• AskBio
• Human Stem Cells Institute
• Novartis

Other notable players include uniQure, Voyager Therapeutics, and Oxford BioMedica.

Drivers and Opportunities:

• Growing prevalence of cardiovascular diseases: Cardiovascular diseases are the leading cause of death globally, with increasing prevalence due to factors like unhealthy lifestyles, aging populations, and rising obesity rates. This creates a significant unmet medical need that gene therapy can potentially address.
• Advancements in gene therapy technology: Technological advancements in vector development, gene editing tools, and delivery methods are improving the efficacy and safety of gene therapy, making it a more viable treatment option for cardiovascular disorders.
• Increasing investments in gene therapy research and development: Pharmaceutical companies and government agencies are investing heavily in gene therapy research, leading to a growing pipeline of potential therapies for cardiovascular diseases.
• Regulatory approvals and government support: The recent approval of the first gene therapy for a cardiovascular disorder (hemophilia B) has generated excitement and paved the way for future approvals. Additionally, government support for research and development is further facilitating market growth.

Segmentation by Type:

• Viral Gene Therapy: This segment accounts for the largest share of the market due to its high efficiency and long-term expression of therapeutic genes. However, safety concerns remain a challenge.
• Non-viral Gene Therapy: This segment is expected to grow at a faster rate due to its lower safety risks, but advancements are needed to improve its delivery efficiency and transgene expression duration.

Segmentation by Application:

• Heart Disease: This segment holds the largest share due to the high prevalence of conditions like heart failure and coronary artery disease.
• Vascular Disease: This segment is expected to grow faster due to increasing awareness and diagnosis rates of peripheral artery disease and other vascular conditions.

Segmentation by Region:

• North America: Currently holds the largest market share due to high prevalence of cardiovascular diseases, advanced healthcare infrastructure, and strong research capabilities.
• Europe: The second-largest market, with a strong commitment to research and development and supportive regulatory frameworks.
• Asia Pacific: Expected to exhibit the fastest growth due to rising healthcare spending, increasing patient awareness, and government initiatives to promote medical innovation.
• South America and Middle East & Africa: These regions are expected to witness moderate growth due to developing healthcare infrastructure and limited access to advanced treatment options.

Overall, the gene therapy in cardiovascular disorder market offers significant growth potential due to the rising prevalence of cardiovascular diseases, advancements in technology, and increasing investments and government support.

With continued research and development, gene therapy has the potential to revolutionize the treatment of cardiovascular disorders and improve patient outcomes.